Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Operating Leases (2022 - 2025)

Historic Operating Leases for Exagen (XGN) over the last 4 years, with Q3 2025 value amounting to $759000.0.

  • Exagen's Operating Leases fell 6111.68% to $759000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $759000.0, marking a year-over-year decrease of 6111.68%. This contributed to the annual value of $1.7 million for FY2024, which is 3971.01% down from last year.
  • Latest data reveals that Exagen reported Operating Leases of $759000.0 as of Q3 2025, which was down 6111.68% from $1.1 million recorded in Q2 2025.
  • Exagen's Operating Leases' 5-year high stood at $6.2 million during Q1 2022, with a 5-year trough of $759000.0 in Q3 2025.
  • Its 4-year average for Operating Leases is $3.2 million, with a median of $2.8 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 3244.02% in 2023, then tumbled by 6111.68% in 2025.
  • Exagen's Operating Leases (Quarter) stood at $4.5 million in 2022, then plummeted by 38.57% to $2.8 million in 2023, then crashed by 39.71% to $1.7 million in 2024, then crashed by 54.39% to $759000.0 in 2025.
  • Its Operating Leases was $759000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $1.4 million in Q1 2025.